

Laurent P Rivory

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3226033/laurent-p-rivory-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76
papers

3,167
citations

28
h-index

55
g-index

80
ext. papers

3,374
ext. citations

5.4
avg, IF

4.79
L-index

#	Paper	IF	Citations
76	Intended transcriptional silencing with siRNA results in gene repression through sequence-specific off-targeting. <i>Rna</i> , 2010 , 16, 430-41	5.8	15
75	Competition between siRNA duplexes: impact of RNA-induced silencing complex loading efficiency and comparison between conventional-21 bp and Dicer-substrate siRNAs. <i>Oligonucleotides</i> , 2010 , 20, 27-32		17
74	Primary leukocyte screens for innate immune agonists. <i>Journal of Biomolecular Screening</i> , 2009 , 14, 723-30		12
73	Sequence determinants of innate immune activation by short interfering RNAs. <i>BMC Immunology</i> , 2009 , 10, 40	3.7	46
72	Interfering ribonucleic acids that suppress expression of multiple unrelated genes. <i>BMC Biotechnology</i> , 2009 , 9, 57	3.5	3
71	Dz13, a DNAzyme targeting c-jun, induces off-target cytotoxicity in endothelial cells with features of nonapoptotic programmed cell death. <i>Oligonucleotides</i> , 2008 , 18, 257-68		7
70	Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. <i>Clinical Cancer Research</i> , 2008 , 14, 817-25	12.9	81
69	Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 82, 33-40	6.1	119
68	Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2007 , 63, 67-74	3.8	14
67	Inhibition of topoisomerase I cleavage activity by thiol-reactive compounds: importance of vicinal cysteines 504 and 505. <i>Journal of Biological Chemistry</i> , 2007 , 282, 14403-12	5.4	18
66	Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules. <i>British Journal of Cancer</i> , 2007 , 97, 1071-6	8.7	25
65	Cytotoxic G-rich oligodeoxynucleotides: putative protein targets and required sequence motif. <i>Nucleic Acids Research</i> , 2007 , 35, 4562-72	20.1	19
64	A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 57, 309-16	3.5	32
63	Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2448-55	2.2	53
62	Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 7492-7	12.9	64
61	The DNAzymes Rs6, Dz13, and DzF have potent biologic effects independent of catalytic activity. <i>Oligonucleotides</i> , 2006 , 16, 297-312		13
60	Predicting the toxicity of weekly docetaxel in advanced cancer. <i>Clinical Pharmacokinetics</i> , 2006 , 45, 611-22		27

59	Solid-Phase Extraction (SPE) Techniques for Sample Preparation in Clinical and Pharmaceutical Analysis: A Brief Overview. <i>Current Pharmaceutical Analysis</i> , 2006 , 2, 95-102	0.6	51
58	The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours. <i>British Journal of Clinical Pharmacology</i> , 2006 , 62, 122-9	3.8	23
57	A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2006 , 94, 964-8	8.7	39
56	Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver. <i>Journal of Pharmacy and Pharmacology</i> , 2005 , 57, 39-45	4.8	6
55	The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 187-200	6.2	118
54	Rapid quantitation of plasma 2 ³ -deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. <i>Journal of Chromatography B: Analytical</i>	3.2	14
53	Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, 33-42	6.1	46
52	Factors affecting cytochrome P-450 3A activity in cancer patients. <i>Clinical Cancer Research</i> , 2004 , 10, 8341-50	12.9	107
51	Population pharmacokinetics of raltitrexed in patients with advanced solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2004 , 57, 416-26	3.8	10
50	Radiosensitization of vinorelbine and gemcitabine in NCI-H460 non-small-cell lung cancer cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 58, 353-60	4	29
49	Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11). <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 76, 505-6; author reply 507-8	6.1	6
48	Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. <i>British Journal of Clinical Pharmacology</i> , 2004 , 57, 44-53	3.8	54
47	Effect of short-term morphine exposure on P-glycoprotein expression and activity in cancer cell lines. <i>Oncology Reports</i> , 2004 , 11, 1091-5	3.5	7
46	The relative contributions of carboxylesterase and β-glucuronidase in the formation of SN-38 in human colorectal tumours. <i>Oncology Reports</i> , 2003 , 10, 1977	3.5	1
45	Carbon monoxide disposition and permeability-surface area product in the foetal circulation of the perfused term human placenta. <i>Placenta</i> , 2003 , 24, 8-11	3.4	16
44	Quantitation of plasma thymidine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. <i>Analytica Chimica Acta</i> , 2003 , 486, 51-61	6.6	12
43	Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. <i>Lancet Oncology</i> , 2003 , 4, 224-32	21.7	181
42	Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy. <i>Nutrition and Cancer</i> , 2003 , 46, 148-57	2.8	68

41	The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours. <i>Oncology Reports</i> , 2003 , 10, 1977-9	3.5	14
40	Lack of beta-tubulin gene mutations in early stage lung cancer. <i>International Journal of Cancer</i> , 2002 , 101, 398-9	7.5	15
39	Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. <i>British Journal of Cancer</i> , 2002 , 87, 277-80	8.7	166
38	The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 303, 649-55	4.7	13
37	Pemetrexed: single-agent and combination phase I study overview. <i>Seminars in Oncology</i> , 2002 , 29, 18-23.5	3.5	298
36	High-performance liquid chromatography-electrospray ionization mass spectrometry method for the measurement of moclobemide and two metabolites in plasma. <i>Biomedical Applications</i> , 2001 , 754, 319-26		16
35	Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-performance liquid chromatography. <i>Biomedical Applications</i> , 2001 , 765, 135-40		15
34	Erythromycin breath test. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 70, 391-394	6.1	3
33	Comment on a published paper. The adverse cholinergic effects of the chemotherapeutic agent irinotecan (CPT-11) were unlikely to be mediated by the inhibition of acetylcholinesterase (AChE). <i>British Journal of Pharmacology</i> , 2001 , 134, 448-50	8.6	
32	The erythromycin breath test for the prediction of drug clearance. <i>Clinical Pharmacokinetics</i> , 2001 , 40, 151-8	6.2	52
31	Carbon monoxide wash-in method to determine gas transfer in vascular beds: application to rat hindlimb. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001 , 280, H1802-6	5.2	4
30	Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction. <i>Anti-Cancer Drugs</i> , 2001 , 12, 619-25	2.4	16
29	Metabolism of CPT-11. Impact on activity. <i>Annals of the New York Academy of Sciences</i> , 2000 , 922, 205-156.5	5.5	22
28	Hepatic disposition of neurotoxins and pesticides. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2000 , 87, 286-91		23
27	Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 45, 9-14	3.5	11
26	Clinical and preclinical pharmacokinetics of raltitrexed. <i>Clinical Pharmacokinetics</i> , 2000 , 39, 429-43	6.2	19
25	Carbon monoxide disposition in the perfused rat liver. <i>American Journal of Physiology - Renal Physiology</i> , 1999 , 277, G725-30	5.1	2
24	The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11). <i>Molecular Pharmacology</i> , 1999 , 56, 1346-53	4.3	53

23	Clinical pharmacokinetics of docetaxel. <i>Clinical Pharmacokinetics</i> , 1999 , 36, 99-114	6.2	328
22	Trace analysis of SN-38 in human plasma by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1998 , 714, 355-9		24
21	The detection of photodegradation products of irinotecan (CPT-11, Campto, Camptosar), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1998 , 17, 785-92	3.5	21
20	Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1997 , 80, 91-6		41
19	Photodegradation of irinotecan (CPT-11) in aqueous solutions: identification of fluorescent products and influence of solution composition. <i>Journal of Pharmaceutical Sciences</i> , 1997 , 86, 1410-6	3.9	21
18	The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1997 , 356, 257-62	3.4	45
17	Relative dispersion of intravascular transit times during isolated human limb perfusions for recurrent melanoma. <i>British Journal of Clinical Pharmacology</i> , 1997 , 44, 347-51	3.8	5
16	Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. <i>Biochemical Pharmacology</i> , 1996 , 52, 1103-11	6	194
15	The effect of oxidative injury on hepatocellular influx of leucine in the rat. <i>International Hepatology Communications</i> , 1996 , 4, 343-350		2
14	Effects of lipophilicity and protein binding on the hepatocellular uptake and hepatic disposition of two anthracyclines, doxorubicin and iododoxorubicin. <i>Cancer Chemotherapy and Pharmacology</i> , 1996 , 38, 439-45	3.5	18
13	Semisynthesis of RPR 121056A, a major metabolite of irinotecan (CPT-11). <i>Tetrahedron Letters</i> , 1996 , 37, 6327-6330	2	6
12	Irinotecan (CPT-11): a brief overview. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1996 , 23, 1000-4	3	32
11	Disposition of epirubicin after intraarterial administration in Lipiodol to patients with hepatocellular carcinoma. <i>Therapeutic Drug Monitoring</i> , 1996 , 18, 537-43	3.2	12
10	Aging, acute oxidative injury and hepatocellular glucose transport in the rat. <i>International Hepatology Communications</i> , 1995 , 3, 244-253		13
9	Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 36, 176-9	3.5	108
8	Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. <i>Biomedical Applications</i> , 1994 , 661, 133-41		77
7	Glucose transport and hypoxia-reoxygenation injury in the perfused rat liver. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1994 , 9, 385-90	4	5
6	The effects of aging and nutritional state on hypoxia-reoxygenation injury in the perfused rat liver. <i>Transplantation</i> , 1994 , 58, 531-6	1.8	21

5	Kinetics of toxic doses of paraquat and the effects of hemoperfusion in the dog. <i>Journal of Toxicology: Clinical Toxicology</i> , 1993 , 31, 229-46		39
4	Physiological pharmacokinetics of solutes in the isolated perfused rat hindlimb: characterization of the physiology with changing perfusate flow, protein content, and temperature using statistical moment analysis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1993 , 21, 653-88		28
3	Aging and the response of the isolated perfused rat liver to vasoactive drugs. <i>Biochemical Pharmacology</i> , 1992 , 43, 913-5	6	5
2	The influence of pH on the interaction of lipophilic anthracyclines with bovine serum albumin. Quantitative characterization by measurement of fluorescence quenching. <i>Biochemical Pharmacology</i> , 1992 , 44, 2347-55	6	13
1	Axial tissue diffusion can account for the disparity between current models of hepatic elimination for lipophilic drugs. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1992 , 20, 19-61		12